Acadia Expects Negative Opinion from EU Regulators for Rett Syndrome Treatment

Dow Jones

02/03

By Kelly Cloonan

Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment.

The company said Monday it was informed by a committee from the European Medicines Agency of a negative trend vote on its marketing authorization application for trofinetide for the treatment of Rett syndrome.

The committee will vote on the application in February, Acadia said.

The company intends to request a re-examination of the opinion upon the formal vote.

Rett syndrome is a rare neurodevelopmental disorder that occurs in about one of every 10,000 to 15,000 female births worldwide. It can cause children to lose motor skills and acquired communication skills.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

February 02, 2026 16:30 ET (21:30 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2608818505"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608818505\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608818505?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608818505","market":"us","top_or_hot":-1,"title":"Acadia Expects Negative Opinion from EU Regulators for Rett Syndrome Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment. \n</p>\n<p>\n  The company said Monday it was informed by a committee from the European Medicines Agency of a negative trend vote on its marketing authorization application for trofinetide for the treatment of Rett syndrome. \n</p>\n<p>\n  The committee will vote on the application in February, Acadia said. \n</p>\n<p>\n  The company intends to request a re-examination of the opinion upon the formal vote. \n</p>\n<p>\n  Rett syndrome is a rare neurodevelopmental disorder that occurs in about one of every 10,000 to 15,000 female births worldwide. It can cause children to lose motor skills and acquired communication skills. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 16:30 ET (21:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Expects Negative Opinion from EU Regulators for Rett Syndrome Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Expects Negative Opinion from EU Regulators for Rett Syndrome Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-03 05:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment. \n</p>\n<p>\n  The company said Monday it was informed by a committee from the European Medicines Agency of a negative trend vote on its marketing authorization application for trofinetide for the treatment of Rett syndrome. \n</p>\n<p>\n  The committee will vote on the application in February, Acadia said. \n</p>\n<p>\n  The company intends to request a re-examination of the opinion upon the formal vote. \n</p>\n<p>\n  Rett syndrome is a rare neurodevelopmental disorder that occurs in about one of every 10,000 to 15,000 female births worldwide. It can cause children to lose motor skills and acquired communication skills. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 16:30 ET (21:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKR","symbol_name":"阿卡迪亚房地产信托","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608818505","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608818505","pubTimestamp":1770067800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment.The company said Monday it was informed by a committee from the European Medicines Agency of a negative trend vote on its marketing authorization application for trofinetide for the treatment of Rett syndrome.The committee will vote on the application in February, Acadia said.The company intends to request a re-examination of the opinion upon the formal vote.Rett syndrome is a rare neurodevelopmental disorder that occurs in about one of every 10,000 to 15,000 female births worldwide. It can cause children to lose motor skills and acquired communication skills.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKR":"阿卡迪亚房地产信托","BK4080":"零售业房地产投资信托","BK4156":"煤与消费用燃料","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","ACAD":"阿卡迪亚","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4231":"零售房地产信托"},"translate_title":"阿卡迪亚预计欧盟监管机构对雷特综合症治疗持负面意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1.5,"ACAD":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment. \n\n\n  The company said Monday it was informed by a committee from the European Medicines Agency of a negative trend vote on its marketing authorization application for trofinetide for the treatment of Rett syndrome. \n\n\n  The committee will vote on the application in February, Acadia said. \n\n\n  The company intends to request a re-examination of the opinion upon the formal vote. \n\n\n  Rett syndrome is a rare neurodevelopmental disorder that occurs in about one of every 10,000 to 15,000 female births worldwide. It can cause children to lose motor skills and acquired communication skills. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 16:30 ET (21:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}